These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Experiences and problems pre-operative anti-CD20 monoclonal antibody infusion therapy with splenectomy and plasma exchange for ABO-incompatible living-donor liver transplantation. Usui M; Isaji S; Mizuno S; Sakurai H; Uemoto S Clin Transplant; 2007; 21(1):24-31. PubMed ID: 17302588 [TBL] [Abstract][Full Text] [Related]
3. Long-term recurrence-free survival after liver transplantation from an ABO-incompatible living donor for treatment of hepatocellular carcinoma exceeding Milano criteria in a patient with hepatitis B virus cirrhosis: a case report. Nakamura Y; Hama K; Iwamoto H; Yokoyama T; Kihara Y; Konno O; Jojima Y; Shimazu M Transplant Proc; 2012 Mar; 44(2):565-9. PubMed ID: 22410070 [TBL] [Abstract][Full Text] [Related]
4. The role of plasmapheresis therapy for perioperative management in ABO-incompatible adult living donor liver transplantation. Ashizawa T; Matsuno N; Yokoyama T; Kihara Y; Kuzuoka K; Taira S; Konno O; Jyojima Y; Akashi I; Nakamura Y; Hama K; Iwamoto H; Iwahori T; Nagao T; Kasahara M; Tanaka K Transplant Proc; 2006 Dec; 38(10):3629-32. PubMed ID: 17175351 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic strategy and the role of apheresis therapy for ABO incompatible living donor liver transplantation. Kozaki K; Egawa H; Kasahara M; Oike F; Yoshizawa A; Fukatsu A; Tanaka K Ther Apher Dial; 2005 Aug; 9(4):285-91. PubMed ID: 16076368 [TBL] [Abstract][Full Text] [Related]
6. New strategy for ABO-incompatible living donor liver transplantation with anti-CD20 antibody (rituximab) and plasma exchange. Kawagishi N; Satoh K; Enomoto Y; Akamatsu Y; Sekiguchi S; Fukumori T; Fujimori K; Satomi S Transplant Proc; 2005 Mar; 37(2):1205-6. PubMed ID: 15848670 [TBL] [Abstract][Full Text] [Related]
9. The role of apheresis therapy for ABO incompatible living donor liver transplantation: the Kyoto University experience. Kozaki K; Egawa H; Ueda M; Oike F; Yoshizawa A; Fukatsu A; Takada Y Ther Apher Dial; 2006 Oct; 10(5):441-8. PubMed ID: 17096700 [TBL] [Abstract][Full Text] [Related]
10. Successful case of adult ABO-incompatible liver transplantation: beneficial effects of intrahepatic artery infusion therapy: a case report. Nakamura Y; Matsuno N; Iwamoto H; Yokoyama T; Kuzuoka K; Kihara Y; Taira S; Sagara T; Jojima Y; Konno O; Tashiro J; Akashi I; Hama K; Narumi K; Iwahori T; Uchiyama M; Tanaka K; Nagao T Transplant Proc; 2004 Oct; 36(8):2269-73. PubMed ID: 15561215 [TBL] [Abstract][Full Text] [Related]
12. Strategic breakthrough in adult ABO-incompatible living donor liver transplantation: preliminary results of consecutive seven cases. Soejima Y; Muto J; Matono R; Ninomiya M; Ikeda T; Yoshizumi T; Uchiyama H; Ikegami T; Shirabe K; Maehara Y Clin Transplant; 2013; 27(2):227-31. PubMed ID: 23293980 [TBL] [Abstract][Full Text] [Related]
13. Rituximab, IVIG, and plasma exchange without graft local infusion treatment: a new protocol in ABO incompatible living donor liver transplantation. Ikegami T; Taketomi A; Soejima Y; Yoshizumi T; Uchiyama H; Harada N; Iguchi T; Hashimoto N; Maehara Y Transplantation; 2009 Aug; 88(3):303-7. PubMed ID: 19667930 [TBL] [Abstract][Full Text] [Related]
14. Effects and problems of adult ABO-incompatible living donor liver transplantation using protocol of plasma exchange, intra-arterial infusion therapy, and anti-CD20 monoclonal antibody without splenectomy: case reports of initial experiences and results in Korea. Kim BW; Park YK; Kim YB; Wang HJ; Kim MW Transplant Proc; 2008 Dec; 40(10):3772-7. PubMed ID: 19100487 [TBL] [Abstract][Full Text] [Related]
15. New protocol of immunosuppression for liver transplantation across ABO barrier: the use of Rituximab, hepatic arterial infusion, and preservation of spleen. Yoshizawa A; Sakamoto S; Ogawa K; Kasahara M; Uryuhara K; Oike F; Ueda M; Takada Y; Egawa H; Tanaka K Transplant Proc; 2005 May; 37(4):1718-9. PubMed ID: 15919443 [TBL] [Abstract][Full Text] [Related]